Angiomax “Not Approvable” For Acute Coronary Syndromes
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Company says FDA letter is "vague"; concerns pertain to non-inferiority design for ACUITY trial.
You may also be interested in...
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY, (Part 1 Of 3)
While fighting for a patent extension for its sales leader, the specialty pharma has adjusted its business model to include acquisitions and early-stage drug development.
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY, (Part 1 Of 3)
While fighting for a patent extension for its sales leader, the specialty pharma has adjusted its business model to include acquisitions and early-stage drug development.
ReceptorBio Licenses Telik’s Diabetes Program
Ex-Telik exec teams with Bay Area diabetes experts to develop insulin receptor activators.